Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

EMA Validates Type II Application for Trastuzumab Deruxtecan in Advanced HER2-Mutated NSCLC

January 4th 2023

The European Medicines Agency has validated an application for the use of trastuzumab deruxtecan for adults with previously treated unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 mutations.

Dr. Velcheti on the Evaluation of Anti-CTLA-4 Combination Regimens in Metastatic NSCLC

January 4th 2023

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Immunotherapy and Targeted Therapy May Represent the Future of Later-line Lung Cancer Treatment

December 27th 2022

Konstantinos Leventakos, MD, PhD, discusses the emergence of immunotherapy and lurbinectedin as beneficial treatments in small cell lung cancer, where osimertinib fits into the non–small cell lung cancer treatment paradigm, and more.

Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

December 23rd 2022

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

December 23rd 2022

Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.

Frontline Domvanalimab Plus Zimberelimab Improves Responses in PD-L1–High Metastatic NSCLC

December 22nd 2022

The combination of domvanalimab plus zimberelimab with or without etrumadenant generated an improvement in overall response rate and progression-free survival compared with zimberelimab alone in patients with PD-L1–high metastatic non–small cell lung cancer, according to findings from the phase 2 ARC-7 trial.

Adagrasib Provides New Option for Patients with KRAS G12C–Mutant NSCLC

December 22nd 2022

The FDA’s accelerated approval of adagrasib for adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer who have received at least 1 prior systemic therapy has provided a second KRAS G12C inhibitor option for patients.

FDA Approves FoundationOne® Liquid CDx as a Companion Diagnostic for TKIs in EGFR-Mutant NSCLC

December 21st 2022

The FDA has approved the FoundationOne® Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions.

FDA Expands Approval of Pemetrexed Injection for Metastatic NSCLC Without EGFR/ALK Aberrations

December 20th 2022

The FDA has approved an additional indication for pemetrexed by injection, an alternative to standard pemetrexed, in combination with pembrolizumab and platinum-based chemotherapy for the initial treatment of patients with metastatic, nonsquamous non–small cell lung cancer without EGFR or ALK genomic tumor aberrations.

Durvalumab Misses OS End Point in PEARL Trial in Advanced, PD-L1–High NSCLC

December 19th 2022

Durvalumab monotherapy failed to elicit a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with stage IV non–small cell lung cancer with at least 25% positivity of PD-L1 on tumor cells, or in a subgroup of patients at low risk of early mortality.

UK Accepts Marketing Authorization Application for Sugemalimab in Metastatic NSCLC

December 19th 2022

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has accepted a marketing authorization application seeking approval for sugemalimab plus chemotherapy as first-line treatment for patients with metastatic non–small cell lung cancer.

FDA Expands Approval for Cytalux Imaging for Lung Cancer Detection

December 19th 2022

The FDA has approved a new indication for pafolacianine to aid surgeons in detecting lung cancer lesions in adult patients with known or suspected lung cancer.

Chemoimmunotherapy Regimens Improve Long-term Outcomes in Small Cell Lung Cancer

December 18th 2022

Stephen V. Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer.

Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

December 16th 2022

Shared perspectives on the emerging strategies for the management of non–small cell lung cancer following the identification of KRAS/STK11, or KRAS/KEAP1 mutations.

Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

December 16th 2022

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

December 16th 2022

Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.

Addressing Inadequate Molecular Testing in Patients With NSCLC

December 16th 2022

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.